Dr Reddy’s aims to launch generic obesity drug at 60% discount

- ADVERTISEMENT -

HYDERABAD, Feb 17 (Reuters) – Indian drugmaker Dr Reddy’s laboratories aims to launch a generic version of Novo Nordisk’s blockbuster weight loss drug Wegovy, subject to approval, at a price about 60% lower than the branded version, co-chairman and managing director GV Prasad told Reuters on Tuesday.

The company last month received an approval from India’s drug regulator to manufacture and sell the generic version of blockbuster diabetes drug Ozempic and said it was awaiting approval for Wegovy.

Related posts:

Analysis: What the ouster of a top FDA regulator shows about Trump world divisions This Indian company is ready to flood the U.S. with cheap HIV drugs India’s Dr Reddy’s plans to launch generic obesity drugs in 87 countries next year, CEO says Vocal FDA critic, Vinay Prasad, to serve as agency’s top vaccine regulator